GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mabpharm Ltd (HKSE:02181) » Definitions » Selling, General, & Admin. Expense

Mabpharm (HKSE:02181) Selling, General, & Admin. Expense : HK$76.50 Mil (TTM As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Mabpharm Selling, General, & Admin. Expense?

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Mabpharm's selling, general, & admin. expense for the six months ended in Dec. 2023 was HK$36.38 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Dec. 2023 was HK$76.50 Mil.


Mabpharm Selling, General, & Admin. Expense Historical Data

The historical data trend for Mabpharm's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mabpharm Selling, General, & Admin. Expense Chart

Mabpharm Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Selling, General, & Admin. Expense
Get a 7-Day Free Trial 46.36 22.00 37.61 56.04 76.50

Mabpharm Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.18 29.15 28.27 40.12 36.38

Competitive Comparison of Mabpharm's Selling, General, & Admin. Expense

For the Biotechnology subindustry, Mabpharm's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mabpharm's Selling, General, & Admin. Expense Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mabpharm's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Mabpharm's Selling, General, & Admin. Expense falls into.



Mabpharm Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$76.50 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mabpharm  (HKSE:02181) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Mabpharm Selling, General, & Admin. Expense Related Terms

Thank you for viewing the detailed overview of Mabpharm's Selling, General, & Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Mabpharm (HKSE:02181) Business Description

Industry
Traded in Other Exchanges
N/A
Address
Lujia Road East, Koutai Road West, Block G79, China Medical City, Taizhou, CHN, 225300
Mabpharm Ltd is a biopharmaceutical company. The company is engaged in the research, development, and production of new drugs and biosimilars for cancers and autoimmune diseases. Its core products include CMAB008 (infliximab), CMAB007 (omalizumab), and CMAB009 (cetuximab).
Executives
Guo Jianjun 2307 Founder of a discretionary trust who can infl
Asia Mabtech Limited
Asia Pacific Immunotech Venture Limited
Guo Family (ptc) Limited
Fortune-healthy Investment Limited
Link Best Capital Limited
Cdh Fund V, L.p.
Cdh Mabtech Limited
Cdh V Holdings Company Limited
China Diamond Holdings Company Limited
China Diamond Holdings V Limited

Mabpharm (HKSE:02181) Headlines

No Headlines